<DOC>
	<DOCNO>NCT00646750</DOCNO>
	<brief_summary>To evaluate efficacy ( complete response rate ) Ybritumomab Tiuxetan ( Zevalin ) administration condition treatment patient refractory large B-cell diffuse lymphoma submit autologous transplantation peripheral blood haematopoietic stem cell .</brief_summary>
	<brief_title>Transplantation With Ybritumomab Tiuxetan ( Zevalin ) Plus BEAM Regimen Patients With Refractory Large B-cell Difusse Lymphom</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Give write informed consent . 2 . Abide least one follow condition : Obtain partial response firstline chemotherapy include anthracyclines + rituximab ( RCHOP , RMegaCHOP , REPOCH like ) , else Absence partial response receive salvage ( postinduction ) chemotherapy include RIFE , RESHAP , RICE like . Patients first recidivation attain partial remission salvage chemotherapy . Patients transform lymphoma , first partial remission ( No CR ) . 3 . Stable disease time transplantation . 4 . Age ≥ 18 ≤ 70 . 5 . Life expectancy great three month . Additionally , able undergo haematopoietic stem cell transplantation , patient satisfy requirement routine clinical practice , i.e . : 1 . Performance status ( ECOG ) &lt; 3 . 2 . FEV1 , DLCO FVC ≥ 50 % normal theoretical value . 3 . Ventricular ejection fraction ( echocardiography isotope ventriculography ) ≥ 50 % . 4 . Total bilirubin transaminase &lt; 3 time normal maximum value , except attributable underlying disease . 5 . Creatinine &lt; 2 time maximum normal value , creatinine clearance &gt; 40 ml/min , except attributable underlying disease . 6 . Absence symptomatic heart disease , cirrhosis active B C virus hepatitis . 7 . HIV negative . 1 . Impossibility collecting , via apheresis , number CD34+ cell ≥ 2 x 106/kg . 2 . Known hypersensitivity mouse proteins . 3 . Involvement CNS lymphoma . 4 . Progressive lymphoma month prior date transplantation . 5 . Previous radioimmunotherapy . 6 . Previous autologous transplantation haematopoietic stem cell . 7 . Pregnant breastfeed woman , adult childbearing age use effective contraceptive method . 8 . Being submit treatment clinical trial 30 day prior entry trial . 9 . Active psychiatric disease , include addiction disorder . 10 . Existence active nothaematopoietic neoplasia , exception cutaneous basal carcinoma cervix intraepithelial carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Z-BEAM</keyword>
	<keyword>Autologous</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>GELTAMO</keyword>
</DOC>